<DOC>
	<DOCNO>NCT00216489</DOCNO>
	<brief_summary>The purpose study confirm safety effectiveness rabeprazole treatment patient erosive ulcerative gastroesophageal reflux disease ( GERD ) routine primary health care .</brief_summary>
	<brief_title>A Study Safety Rabeprazole Administered Adults With Gastroesophageal Reflux Disease ( GERD )</brief_title>
	<detailed_description>Gastroesophageal reflux result mild severe symptom person . Heartburn , burn sensation discomfort rise behind breastbone , common symptom . Gastroesophageal reflux disease ( GERD ) describe condition clearly identify clinical symptom change tissue structure result reflux content stomach small intestine esophagus . This study confirm safety effectiveness rabeprazole treatment patient GERD routine primary health care . The study two phase . Patients receive treatment rabeprazole tablet daily 8 week . In second phase , patient monitor physician follow period end study ( 12 month ) . Safety assessment include incidence adverse event throughout treatment follow phase , physical examination laboratory test end treatment 4 month . Assessments effectiveness include degree relief symptom begin end treatment specific interval follow . The study hypothesis rabeprazole well-tolerated long term treatment patient GERD routine primary health care . Rabeprazole tablet ( 20 milligram [ mg ] ) daily morning 8 week . Dose may increase 2 tablet daily ( 40 mg maximum ) investigator 's discretion .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Patients symptom erosive ulcerative gastroesophageal reflux disease ( GERD ) least period 3 month prior study initiation symptom GERD least 3 day per week within 2 week prior study initiation . The symptom erosive ulcerative gastroesophageal reflux disease include follow : heartburn , ache behind breastbone , need antacid , difficulty swallow . Patients evidence endoscopy erosive ulcerative gastroesophageal reflux disease Barrettype tissue transformation . No narrow inflammation esophagus know gastroduodenal ulcer infection ( H. Pylori ) , inflammation hemorrhage stomach , small large intestine prior surgery stomach intestine know history primary kinetic disorder esophagus , GERD history enlarge vein esophagus stomach pregnant nursing female , lack adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>gastroesophageal reflux</keyword>
	<keyword>heartburn</keyword>
	<keyword>rabeprazole</keyword>
	<keyword>GERD</keyword>
	<keyword>anti-ulcer agent</keyword>
	<keyword>proton pump inhibitor</keyword>
</DOC>